ImmuneOncia Therapeutics

Fully human IgG1 monoclonal antibody against PD-L1 that blocks PD-1/PD-L1 binding and induces ADCC. In January 2026 the MFDS designated it an orphan drug for relapsed or refractory extranodal NK/T-cell lymphoma (ENKTL); in phase 2 it showed a 79% objective response rate and a 63% complete response rate.

Next-generation monoclonal antibody against CD47. A phase 1b trial combined it with paclitaxel or gemcitabine plus carboplatin in triple-negative breast cancer (TNBC), and in August 2026 a pancreatic ductal adenocarcinoma cohort combining it with lenvatinib was approved.

PD-L1/CD47 IgG1 bispecific antibody developed in-house from IMC-001 and IMC-002 as parent antibodies.

Immuno-oncology platform targeting T cells and macrophages, used to expand the pipeline across anti-PD-L1, anti-LAG-3, anti-CD47 and other mechanisms.

Danburstotug (IMC-001) was designated an orphan drug by the MFDS for relapsed or refractory NK/T-cell lymphoma.

Signed a CDMO agreement with Lonza to prepare Danburstotug for commercialisation, with drug substance at Slough, U.K., and drug product at Basel and Stein, Switzerland.

Presented phase 1b results for IMC-002 in TNBC at ASCO 2026: in 12 patients, a 25% objective response rate and a 75% disease control rate, with no thrombocytopenia or leukopenia observed, according to the company.

The MFDS approved an amendment adding a pancreatic ductal adenocarcinoma cohort with lenvatinib to the IMC-002 phase 1b trial; enrolment starts at Samsung Medical Center in October 2026.